Home » Topics » BioWorld Science, Immune

BioWorld Science, Immune
RSS

Novel thalidomide prodrugs reported in patent literature

Jan. 12, 1998

ABX-CBL evaluated in phase II GVHD trial

Jan. 7, 1998

New immunosuppressants in the pipeline at Merck & Co.

Dec. 31, 1997

MedImmune and BioTransplant plan to test MEDI-507 for graft-vs.-host disease

Dec. 29, 1997

CY-1503 reduces reperfusion injury in a dog lung allograft model

Dec. 22, 1997

In vitro and in vivo immunosuppressive effects of FTY-720

Dec. 22, 1997

HHS announces intention to out-license vaccine technology

Dec. 19, 1997

LJP-394 binds to B-cells in lupus patients

Dec. 17, 1997

La Jolla evaluates Toleragan compounds for xenotransplantation

Dec. 17, 1997

SmithKline Beecham licenses rotavirus vaccine

Dec. 16, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...